Advaxis Inc. (ADXS)

0.76
0.01 1.80
NASDAQ : Health Technology
Prev Close 0.77
Open 0.78
Day Low/High 0.75 / 0.79
52 Wk Low/High 0.76 / 4.24
Volume 416.18K
Avg Volume 918.90K
Exchange NASDAQ
Shares Outstanding 69.23M
Market Cap 55.22M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended...

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis, Inc. (NASDAQ:ADXS) ("Advaxis" or the "Company") announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company") announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a...

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development...

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a clinical update, as follows: Plans to withdraw its Conditional Marketing Authorization...

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an...

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and...

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial...

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer...

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of...

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has...

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology At AACR 2018

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology At AACR 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies...

Advaxis To Present At Upcoming March Conferences

Advaxis To Present At Upcoming March Conferences

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company...

Short Interest In Advaxis Drops 36.7%

Short Interest In Advaxis Drops 36.7%

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 3,020,486 share decrease in total short interest for Advaxis Inc , to 5,217,154, a decrease of 36.67% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended...

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLMN, CENX, MMYT, ULH, USM Downgrades: CVV, DGICA, DGICB, INT, MELI, RMAX, VLP Initiations: ADXS Read on to get TheStreet Quant Ratings' detailed report:

Advaxis Prices $20.0 Million Public Offering Of Common Stock

Advaxis Prices $20.0 Million Public Offering Of Common Stock

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of...

Advaxis Announces Proposed Public Offering Of Common Stock

Advaxis Announces Proposed Public Offering Of Common Stock

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends...

Advaxis Submits Conditional Marketing Authorization Application For Axalimogene Filolisbac For The Second-Line Treatment Of Metastatic Cervical Cancer In European Union

Advaxis Submits Conditional Marketing Authorization Application For Axalimogene Filolisbac For The Second-Line Treatment Of Metastatic Cervical Cancer In European Union

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization...

Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that data from an earlier Phase 2 clinical study of...

Short Interest Expands By 10% For ADXS

Short Interest Expands By 10% For ADXS

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 751,352 share increase in total short interest for Advaxis Inc , to 8,236,371, an increase of 10.04% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Data Highlighting Advaxis' Antigen Delivery Platform Accepted For Multiple Presentations At 2018 Keystone Symposia Conference On Cancer Immunotherapies

Data Highlighting Advaxis' Antigen Delivery Platform Accepted For Multiple Presentations At 2018 Keystone Symposia Conference On Cancer Immunotherapies

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Company's...

Advaxis' Immunotherapy In Combination With Chemoradiation Highlighted As Potential Treatment For Anal Cancer In International Journal Of Radiation Oncology

Advaxis' Immunotherapy In Combination With Chemoradiation Highlighted As Potential Treatment For Anal Cancer In International Journal Of Radiation Oncology

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated...

TheStreet Quant Rating: E+ (Sell)